Statin use and the risk of pancreatic cancer: A population-based case-control study

Pancreas

Volumn 40, Issue 5, 2011, Pages 669-672

  Chiu, Hui Fen ^a   Chang, Chih Ching ^b   Ho, Shu Chen ^c   Wu, Trong Neng ^d,e   Yang, Chun Yuh ^c,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

case control study; pancreatic cancer; Pharmacoepidemiology; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CANCER RISK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TAIWAN;

AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ODDS RATIO; PANCREATIC NEOPLASMS; PHARMACOEPIDEMIOLOGY; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN;

EID: 79959829952     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31821fd5cd     Document Type: Article

References (45)

1. Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16:508-519. (Pubitemid 34460459)
2. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 1997;278:313-321.
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366:1267-1278.
4. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA. 1996;275:55-60. (Pubitemid 26004257)
5. Keyomarsi K, Sandoval L, Band V, et al. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991;51:3602-3609.
6. Dimitroulakos J, Marhin WH, Tokunaga J, et al. Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinoma. Neoplasia. 2002;4:337-346. (Pubitemid 34755844)
7. Weis M, Heeschen C, Glassford AJ, et al. Statins have biphasic effects on angiogenesis. Circulation. 2002;105:739-745. (Pubitemid 34157379)
8. Park HJ, Hong D, Iruela-Arispe L, et al. 3-Hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res. 2002;91:143-150. (Pubitemid 34827225)
9. Alonso DF, Farina HG, Skilton G, et al. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat. 1998;50:83-93. (Pubitemid 28438864)
10. Kusama T, Mukai M, Iwasaki T, et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology. 2002;122:308-317. (Pubitemid 34116983)
11. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004;90:635-637. (Pubitemid 38297203)
12. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: A meta-analysis. JAMA. 2006;295:74-80. (Pubitemid 43042692)
13. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology. 2007;18:213-219.
14. Browning DR, Martin RM. Statins and risk of cancer: A systematic review and metaanalysis. Int J cancer. 2006;120:833-843.
15. Bonovas S, Filioussi K, Tsavaris N, et al. Statins and cancer risk: A literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol. 2006;24:4808-4817. (Pubitemid 46655612)
16. Setoguchi S, Glynn RJ, Avorn J, et al. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007;115:27-33. (Pubitemid 46058608)
17. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A lsystematic review and meta-analysis. Eur J Cancer. 2008;44:2122-2132.
18. Haukka J, Sankila R, Klaukka T, et al. Incidence of cancer and statin usage-record linkage study. Int J Cancer. 2010;126:279-284.
19. Cauley JA, Zmuda JM, Lui LY, et al. Lipid-lowering drug use and breast cancer in older women: A prospective study. J Womens Health. 2003;12:749-756. (Pubitemid 37361917)
20. Boudreau DM, Gardner JS, Malone KE, et al. The association between 3-hydroxy-3-methylglutaryl-coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women. Cancer. 2004;100:2308-2316. (Pubitemid 38657877)
21. Graaf MR, Beiderbeck AB, Egberts AC, et al. The risk of cancer in users of statins. J Clin Oncol. 2004;22:2388-2394. (Pubitemid 41115396)
22. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch Intern Med. 2000;160:2363-2368.
23. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184-2192. (Pubitemid 40727085)
24. Shannon J, Tewoderos S, Garzotto M, et al. Statins and prostate cancer risk: A case-control study. Am J Epidemiol. 2005;162:318-325. (Pubitemid 41389713)
25. Khurana V, Bejjanki HR, Caldito G, et al. Statins reduce the risk of lung cancer: A large case-control study of US veterans. Chest. 2007;131:1282-1288. (Pubitemid 46762329)
26. Khurana V, Sheth A, Caldito G, et al. Statins reduce the risk of pancreatic cancer in humans: A case-control study of half a million veterans. Pancreas. 2007;34:260-265. (Pubitemid 46294804)
27. El-Serag HB, Johnson ML, Hachem C, et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136:1601-1608.
28. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: A population-based cohort study. Int J Cancer. 2005;114:643-647. (Pubitemid 40349625)
29. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 1988;62:28J-34J. (Pubitemid 18263853)
30. Kuo HW, Tsai SS, Tiao MM, et al. Epidemiologic features of CKD in Taiwan. Am J Kidney Dis. 2007;49:46-55.
31. Chiang CW, Chen CY, Chiu HF, et al. Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf. 2007;16:412-421.
32. Tiao MM, Tsai SS, Kuo HW, et al. Epidemiological features of biliary atresia in Taiwan, a national study 1996-2003. J Gastroenterol Hepatol. 2008;23:62-66.
33. Coogan PF, Rosenberg L, Palmer JR, et al. Statin use and the risk of breast and prostate cancer. Epidemiology. 2002;13:262-267. (Pubitemid 34415845)
34. Meier CR, Scheinger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000;283:3205-3210. (Pubitemid 30422037)
35. Wang PS, Solomon DH, Mogun H, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000;283:3211-3216. (Pubitemid 30422038)
36. Rejnmark L, Plsen ML, Johnsen SP, et al. Hip fracture risk in statin usersVa population-based Danish case-control study. Osteoporos Int. 2004;15:452-458. (Pubitemid 38843173)
37. Jadhav SB, Jain GK. Statins and osteoporosis: New role for old drugs. J Pharm Pharmacol. 2006;58:3-18. (Pubitemid 43041991)
38. WHO Collaborating Center for Drugs Statistics Methodology. ATC Index With DDDs 2003. Oslo: WHO; 2003.
39. Hart AR, Kennedy H, Harvey I. Pancreatic cancer: A review of the evidence on causation. Clin Gastroenterol Hepatol. 2008;6:275-282. (Pubitemid 351318383)
40. Danesh FR, Sadeghi MM, Amro N, et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci. 2002;99:8301-8305. (Pubitemid 34651047)
41. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719. (Pubitemid 34219772)
42. Blanco-Colio LM, Villa A, Ortego M, et al. 3-Hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis. 2002;161:17-26. (Pubitemid 34214817)
43. Kusama T, Mukai M, Iwasaki T, et al. Inhibition of epidermal growth factor induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors. Cancer Res. 2001;61:4885-4891. (Pubitemid 32691906)
44. Shibata MA, Avanaugh C, Shibata E, et al. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis. 2003;24:453-459. (Pubitemid 36432640)
45. Rao S, Porter DC, Chen X, et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci. 1999;96:7797-7802. (Pubitemid 29328361)